Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Share-based Compensation data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 19.86% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $26.4 million, down 8.54%, while the annual FY2025 figure was $26.4 million, 8.54% down from the prior year.
  • Share-based Compensation reached $6.0 million in Q4 2025 per TNGX's latest filing, down from $6.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.5 million in Q2 2024 and bottomed at $950000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.8 million, with a median of $4.9 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 325.05% in 2021, then fell 19.86% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.3 million in 2021, then surged by 67.7% to $3.8 million in 2022, then increased by 28.9% to $4.9 million in 2023, then skyrocketed by 52.94% to $7.5 million in 2024, then dropped by 19.86% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $6.0 million in Q4 2025, $6.6 million in Q3 2025, and $6.6 million in Q2 2025.